Search

Your search keyword '"Millard, Frederick"' showing total 164 results
Start Over Author "Millard, Frederick"
164 results on '"Millard, Frederick"'

2. Evaluation and Management of Testicular Cancer After Late Relapse

Author

Langner, Joanna L., Millard, Frederick, Vavinskaya, Vera, Zhang, Haiyan, Yodkhunnatham, Nuphat, and Bagrodia, Aditya

Subjects
Glycoproteins, Diseases -- Relapse, Chorionic gonadotropin, Cancer -- Diagnosis -- Care and treatment, Health
Abstract

A 41-year-old man presented to his primary care physician with a 1-month history of left neck adenopathy in the context of a history of nonseminomatous germ cell tumors (NSGCTs). In 2011, the patient was treated for stage IB (T2N0M0S0) right-sided NSGCTs of the testis, which were 95% embryonal and 5% yolk sac tumors. He underwent a right radical orchiectomy and was followed until 2022 without recurrence. In the work-up for his adenopathy, laboratory results for human chorionic gonadotropin, lactate dehydrogenase, and [alpha]-fetoprotein were normal. CT scans confirmed clustered enlarged lymph nodes in the left lower spinal accessory posterior triangle, enlarged left lower neck lymph nodes, and several foci of enlarged left retroperitoneal periaortic lymph nodes. Fine needle aspiration of a left neck lymph node identified malignant tumor cells. A left neck dissection showed embryonal carcinoma in 12 of 28 nodes. Immunostaining showed the tumor cells were positive for SALL4 and CD30 but negative for CD117. This patient likely had a contralateral late relapse of his original right NSGCT after 11 years of remission. The patient's original cancer was on the right side, with recurrence surrounding the aorta on the contralateral side, representing an atypical pattern of spread., Case Report A 41-year-old Asian man presented to his primary care physician (PCP) in January 2023 with a 1-month history of left neck adenopathy in the context of a prior [...]

Published
2024

3. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)

Author

Pachynski, Russell K, Morishima, Chihiro, Szmulewitz, Russell, Harshman, Lauren, Appleman, Leonard, Monk, Paul, Bitting, Rhonda L, Kucuk, Omer, Millard, Frederick, Seigne, John D, Fling, Steven P, Maecker, Holden T, Duault, Caroline, Ramchurren, Nirasha, Hess, Bruce, D’Amico, Leonard, Lacroix, Andreanne, Kaiser, Judith C, Morre, Michel, Grégoire, Anne, Cheever, Martin, Yu, Evan Y, and Fong, Lawrence

Subjects
Cancer, Immunization, Urologic Diseases, Vaccine Related, Prostate Cancer, Inflammatory and immune system, Good Health and Well Being, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cohort Studies, Humans, Interleukin-7, Lymphocyte Activation, Lymphocytes, Male, Middle Aged, Neoplasm Metastasis, Neutrophils, Prospective Studies, Prostatic Neoplasms, Castration-Resistant, Recombinant Proteins, Tissue Extracts, prostatic neoplasms, clinical trials as topic, immunotherapy, cytokines, T-lymphocytes
Abstract

Sipuleucel-T (sip-T) is a Food and Drug Administration (FDA)-approved autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). We hypothesized that combining sip-T with interleukin (IL)-7, a homeostatic cytokine that enhances both B and T cell development and proliferation, would augment and prolong antigen-specific immune responses against both PA2024 (the immunogen for sip-T) and prostatic acid phosphatase (PAP). Fifty-four patients with mCRPC treated with sip-T were subsequently enrolled and randomized 1:1 into observation (n=26) or IL-7 (n=28) arms of a phase II clinical trial (NCT01881867). Recombinant human (rh) IL-7 (CYT107) was given weekly×4. Immune responses were evaluated using flow cytometry, mass cytometry (CyTOF), interferon (IFN)-γ ELISpot, 3H-thymidine incorporation, and ELISA. Treatment with rhIL-7 was well tolerated. For the rhIL-7-treated, but not observation group, statistically significant lymphocyte subset expansion was found, with 2.3-2.6-fold increases in CD4+T, CD8+T, and CD56bright NK cells at week 6 compared with baseline. No significant differences in PA2024 or PAP-specific T cell responses measured by IFN-γ ELISpot assay were found between rhIL-7 and observation groups. However, antigen-specific T cell proliferative responses and humoral IgG and IgG/IgM responses significantly increased over time in the rhIL-7-treated group only. CyTOF analyses revealed pleiotropic effects of rhIL-7 on lymphocyte subsets, including increases in CD137 and intracellular IL-2 and IFN-γ expression. While not powered to detect clinical outcomes, we found that 31% of patients in the rhIL-7 group had prostate specific antigen (PSA) doubling times of >6 months, compared with 14% in the observation group. Treatment with rhIL-7 led to a significant expansion of CD4+ and CD8+ T cells, and CD56bright natural killer (NK) cells compared with observation after treatment with sip-T. The rhIL-7 treatment also led to improved antigen-specific humoral and T cell proliferative responses over time as well as to increased expression of activation markers and beneficial cytokines. This is the first study to evaluate the use of rhIL-7 after sip-T in patients with mCRPC and demonstrates encouraging results for combination approaches to augment beneficial immune responses.

Published
2021

4. Germline alterations among Hispanic men with prostate cancer

Author

Pan, Elizabeth, Shaya, Justin, Madlensky, Lisa, Randall, J. Michael, Javier-Desloges, Juan, Millard, Frederick E., Rose, Brent, Parsons, J. Kellogg, Nielsen, Sarah M., Hatchell, Kathryn E., Esplin, Edward D., Nussbaum, Robert L., Weise, Nicole, Murphy, James, Martinez, Maria Elena, and McKay, Rana R.

Published
2022
Full Text
View/download PDF

6. MP01-07 IMPACT OF CHEMOTHERAPY ON ANXIETY, DEPRESSION, AND SUICIDALITY AMONGST TESTICULAR CANCER SURVIVORS

Author

Meagher, Margaret F., primary, Nelson, Tyler, additional, Riviere, Paul, additional, Leonard, Austin, additional, Dolendo, Isabella, additional, Morgan, Kylie, additional, Wang, Luke, additional, Taylor, Jacob, additional, Herchenhorn, Daniel, additional, Stewart, Tyler, additional, Javier-Desloges, Juan, additional, Salmasi, Amirali, additional, McKay, Rana, additional, Millard, Frederick, additional, Rose, Brent, additional, and Bagrodia, Aditya, additional

Published
2024
Full Text
View/download PDF

7. MP61-19 INCIDENCE OF ERECTILE DYSFUNCTION AND TESTOSTERONE DEFICIENCY IN TESTICULAR CANCER SURVIVORS

Author

Pandit, Kshitij, primary, Riviere, Paul, additional, Nelson, Tyler, additional, Meagher, Margaret, additional, Puri, Dhruv, additional, Yodkhunnatham, Nuphat, additional, Morgan, Kylie M., additional, Deshler, Leah N., additional, Duran, Elizabeth A., additional, Sabater-Minarim, Daniel, additional, Javier-Desloges, Juan, additional, Salmasi, Amirali, additional, Mckay, Rana R., additional, Millard, Frederick, additional, Hsieh, Tung-Chin, additional, Patel, Darshan P., additional, Rose, Brent S., additional, Herchenhorn, Daniel, additional, and Bagrodia, Aditya, additional

Published
2024
Full Text
View/download PDF

8. MP01-17 NATURAL HISTORY OF SUBCENTIMETER PULMONARY NODULES IN CLINICAL STAGE I SEMINOMA PATIENTS

Author

Yodkhunnatham, Nuphat, primary, Puri, Dhruv, additional, Pandit, Kshitij, additional, Leonard, Austin, additional, Dolendo, Isabella, additional, Langner, Joanna, additional, Roberts, Jacob, additional, Cortes, Julian, additional, Salmasi, Amirali, additional, Mckay, Rana, additional, Rose, Brent, additional, Millard, Frederick, additional, and Bagrodia, Aditya, additional

Published
2024
Full Text
View/download PDF

9. MP01-16 MOLECULAR DRIVERS OF ORGANOTROPISM AND CISPLATIN RESISTANCE IN GERM CELL TUMORS

Author

Meagher, Margaret F., primary, Sawa, Yun Cheng, additional, Jia, Liwei, additional, Millard, Frederick, additional, Krause, Harris, additional, Farrell, Alex, additional, Elliott, Andrew, additional, Lafin, John, additional, Jamieson, Christina, additional, Antonarakis, Emmanuel, additional, D'Souza, Anishka, additional, Giannikou, Krinio, additional, Amatruda, James, additional, Daneshmand, Siamak, additional, McKay, Rana, additional, Oberly, Matthew, additional, Nabhan, Chadi, additional, and Bagrodia, Aditya, additional

Published
2024
Full Text
View/download PDF

11. Virtual Follow-Up in Patients Initiating Antineoplastic Treatment in the Ambulatory Setting.

Author

Chew, Lauren J., Urman, Danielle S., Maxwell, Kevin, Ajmera, Archana, Millard, Frederick, and McKay, Rana R.

Subjects
PATIENT education, RESEARCH funding, PATIENT safety, MEDICAL quality control, T-test (Statistics), OUTPATIENT medical care, ANTINEOPLASTIC agents, PILOT projects, IMMUNOTHERAPY, RESEARCH methodology evaluation, QUESTIONNAIRES, CANCER patients, DESCRIPTIVE statistics, TELEMEDICINE, GENITOURINARY organ tumors, CANCER chemotherapy, PATIENT satisfaction, PATIENT aftercare
Abstract

PURPOSE: Initiating antineoplastic therapy can be distressful and affect patient retention of treatment-related side effects and safety protocols. Return visits can range from 8 to 28 days after treatment, during which patients may develop treatment-related questions and toxicities. This study's objective is to evaluate how implementing a follow-up phone call 24-48 hours after initial antineoplastic infusion, compared with standard pretreatment education, affects patient satisfaction and education retention. METHODS: We conducted a single-center pilot study where patients who were literate, English-speaking, with genitourinary malignancies, initiating intravenous chemotherapy or immunotherapy were eligible. The primary end point was patient knowledge retention. Secondary end points included patient satisfaction. The Leuven's Questionnaire Patient Knowledge Tool, a validated, standardized tool, was used to evaluate patient knowledge retention, with a higher score indicating more retention. Telephone follow-up was initiated 24-48 hours after initial infusion, where Leuven's Questionnaire was used to assess patient knowledge. A nurse then reinforced treatment-related education, reviewed notification parameters, and coordinated appropriate follow-up. One week later, participants were sent a follow-up Leuven's Questionnaire and standardized patient satisfaction assessment. RESULTS: Thirty-one patients with renal cell carcinoma, prostate, bladder, germ cell/testicular, or adrenal cancers were included in the study. Mean preintervention Leuven's Questionnaire score was 5.3 and mean postintervention score was 8.1 on a 1-10 scale (P <.0001). Ninety-seven percent of patients reported improved satisfaction postintervention. CONCLUSION: Proactive telephonic follow-up for oncology patients improves education retention, patient satisfaction, and has potential to improve patient safety and quality of care. Telephonic follow-up for oncology patients postinfusion improves satisfaction and quality of care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis

Author

Field, Charles A., Cotta, Brittney H., Jimenez, Juan, Lane, Brian R., Yim, Kendrick, Lee, Hak J., Ryan, Stephen T., Hamilton, Zachary A., Patel, Sunil, Wang, Song, Kane, Christopher J., Dey, Sumi, Mckay, Rana R., Noyes, Sabrina, Millard, Frederick E., Rini, Brian I., Campbell, Steven C., and Derweesh, Ithaar H.

Published
2019
Full Text
View/download PDF

15. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate‐resistant prostate cancer

Author

Aggarwal, Rahul, Halabi, Susan, Kelly, William Kevin, George, Daniel, Mahoney, John F, Millard, Frederick, Stadler, Walter M, Morris, Michael J, Kantoff, Philip, Monk, J Paul, Carducci, Michael, Small, Eric J, and Oncology, for the Alliance for Clinical Trials in

Subjects
Prostate Cancer, Clinical Research, Urologic Diseases, Clinical Trials and Supportive Activities, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Aged, Androgen Antagonists, Antibodies, Monoclonal, Humanized, Antifungal Agents, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Bone Neoplasms, Chemotherapy, Adjuvant, Disease Progression, Docetaxel, Drug Therapy, Combination, Follow-Up Studies, Humans, International Agencies, Ketoconazole, Liver Neoplasms, Lung Neoplasms, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Staging, Orchiectomy, Prednisone, Prognosis, Prostatic Neoplasms, Retrospective Studies, Survival Rate, Taxoids, prostatic neoplasms, chemotherapy, ketoconazole, steroid 17-alpha-hydroxylase, androgen antagonists, Alliance for Clinical Trials in Oncology, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundPreliminary data suggest a potential decreased benefit of docetaxel in patients with metastatic, castration-resistant prostate cancer (mCRPC) who previously received abiraterone acetate, a novel androgen synthesis inhibitor (ASI). Cancer and Leukemia Group B (CALGB) trial 90401 (Alliance), a phase 3 trial in patients with mCRPC who received docetaxel-based chemotherapy, offered the opportunity to evaluate effect of prior ketoconazole, an earlier generation ASI, on clinical outcomes after docetaxel.MethodsIn CALGB trial 90401, 1050 men with chemotherapy-naive mCRPC were randomized to receive treatment with docetaxel and prednisone that included either bevacizumab or placebo. In total, 1005 men (96%) had data available regarding prior ketoconazole therapy. The observed effects of prior ketoconazole on overall survival (OS), progression-free survival (PFS), prostate-specific antigen (PSA) decline, and the objective response rate (ORR) were assessed using proportional hazards and Poisson regression methods adjusted for validated prognostic factors and treatment arm.ResultsBaseline characteristics between patients who did (N=277) and did not (N=728) receive prior ketoconazole therapy were similar. There were no statistically significant differences between patients who did and those who did not receive prior ketoconazole therapy with respect to OS (median OS, 21.1 months vs 22.3 months, respectively; stratified log-rank P=.635), PFS (median PFS, 8.1 months vs 8.6 months, respectively; stratified log-rank P=.342), the proportion achieving a decline ≥ 50% in PSA (61% vs 66%, respectively; relative risk, 1.09; adjusted P=.129), or ORR (39% vs 43%, respectively; relative risk, 1.11; adjusted P=.366).ConclusionsAs measured by OS, PFS, PSA, and the ORR, there was no evidence that prior treatment with ketoconazole had an impact on the clinical outcomes of patients with mCRPC who received subsequent docetaxel-based therapy. The current results highlight the need for prospective studies to assess for potential cross-resistance with novel ASIs and to define the optimal sequence of therapy in mCRPC.

Published
2013

29. Immunogenic HLA-B7-restricted peptides of hTRT

Author

Cortez-Gonzalez, Xochitl, Sidney, John, Adotevi, Olivier, Sette, Alessandro, Millard, Frederick, Lemonnier, Francois, Langlade-Demoyen, Pierre, and Zanetti, Maurizio

Published
2006

31. Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic factors: a phase II Cancer and Leukemia Group B Study

Author

Wasserman, Todd H., Petroni, Gina R., Millard, Frederick E., Chung, Chung-Taik, Barcos, Maurice, Johnson, Jeff L., Canellos, George P., and Peterson, Bruce A.

Subjects
Hodgkin's disease -- Care and treatment, Etoposide -- Evaluation, Vinblastine -- Evaluation, Doxorubicin -- Evaluation, Health
Published
1999

33. Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Author

Coccia, Peter F., primary, Pappo, Alberto S., additional, Beaupin, Lynda, additional, Borges, Virginia F., additional, Borinstein, Scott C., additional, Chugh, Rashmi, additional, Dinner, Shira, additional, Folbrecht, Jeanelle, additional, Frazier, A. Lindsay, additional, Goldsby, Robert, additional, Gubin, Alexandra, additional, Hayashi, Robert, additional, Huang, Mary S., additional, Link, Michael P., additional, Livingston, John A., additional, Matloub, Yousif, additional, Millard, Frederick, additional, Oeffinger, Kevin C., additional, Puccetti, Diane, additional, Reed, Damon, additional, Robinson, Steven, additional, Rosenberg, Abby R., additional, Sanft, Tara, additional, Spraker-Perlman, Holly L., additional, von Mehren, Margaret, additional, Wechsler, Daniel S., additional, Whelan, Kimberly F., additional, Yeager, Nicholas, additional, Gurski, Lisa A., additional, and Shead, Dorothy A., additional

Published
2018
Full Text
View/download PDF

34. Rate of occult metastases in patients (pts) with biochemically-recurrent prostate cancer (BRPC) from a phase 2 trial of sipuleucel-T and androgen deprivation therapy (STAND).

Author

Kibel, Adam S., primary, Drake, Charles G., additional, Yu, Evan Y., additional, Vogelzang, Nicholas J., additional, Corman, John M., additional, Karsh, Lawrence Ivan, additional, Elfiky, Aymen, additional, Shore, Neal D., additional, Millard, Frederick E., additional, Chang, Nancy N., additional, and Antonarakis, Emmanuel S., additional

Published
2017
Full Text
View/download PDF

35. Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial

Author

Antonarakis, Emmanuel S., primary, Kibel, Adam S., additional, Yu, Evan Y., additional, Karsh, Lawrence I., additional, Elfiky, Aymen, additional, Shore, Neal D., additional, Vogelzang, Nicholas J., additional, Corman, John M., additional, Millard, Frederick E., additional, Maher, Johnathan C., additional, Chang, Nancy N., additional, DeVries, Todd, additional, Sheikh, Nadeem A., additional, and Drake, Charles G., additional

Published
2017
Full Text
View/download PDF

36. Long-term follow-up from STAMP, a phase II trial, evaluating sipuleucel-T and concurrent (CON) vs sequential (SEQ) abiraterone acetate + prednisone in metastatic castration-resistant prostate cancer patients (pts).

Author

Small, Eric Jay, primary, Lance, Raymond S., additional, Redfern, Charles H., additional, Millard, Frederick E., additional, Gardner, Thomas A., additional, Dawson, Nancy Ann, additional, Fong, Lawrence, additional, Karsh, Lawrence Ivan, additional, Corman, John M., additional, Nordquist, Luke T., additional, Murdock, Myron I, additional, Curti, Brendan D., additional, Chang, Nancy N., additional, and Shore, Neal D., additional

Published
2017
Full Text
View/download PDF

37. Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma

Author

Hamilton, Zachary, primary, Lee, Hak J., additional, Jimenez, Juan, additional, Lane, Brian R., additional, Wang, Song, additional, Beksac, Alp T., additional, Gillis, Kyle, additional, Alagh, Amy, additional, Tobert, Conrad, additional, Randall, James M., additional, Kane, Christopher J., additional, Millard, Frederick, additional, Campbell, Steven C., additional, and Derweesh, Ithaar H., additional

Published
2016
Full Text
View/download PDF

38. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)

Author

Aggarwal, Rahul, Halabi, Susan, Kelly, William Kevin, George, Daniel, Mahoney, John F, Millard, Frederick, Stadler, Walter M, Morris, Michael J, Kantoff, Philip, Monk, J Paul, Carducci, Michael, Small, Eric J, and Alliance for Clinical Trials in Oncology

Subjects
Male, Urologic Diseases, Lung Neoplasms, Antifungal Agents, ketoconazole, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Bone Neoplasms, Docetaxel, chemotherapy, Antibodies, prostatic neoplasms, steroid 17-alpha-hydroxylase, Drug Therapy, Clinical Research, Antineoplastic Combined Chemotherapy Protocols, Monoclonal, Humans, Oncology & Carcinogenesis, Humanized, Adjuvant, androgen antagonists, Neoplasm Staging, Retrospective Studies, Aged, Cancer, Alliance for Clinical Trials in Oncology, Prostate Cancer, Liver Neoplasms, International Agencies, Evaluation of treatments and therapeutic interventions, Middle Aged, Prognosis, Survival Rate, Bevacizumab, Lymphatic Metastasis, 6.1 Pharmaceuticals, Combination, Disease Progression, Public Health and Health Services, Prednisone, Taxoids, Orchiectomy, Follow-Up Studies
Abstract

BackgroundPreliminary data suggest a potential decreased benefit of docetaxel in patients with metastatic, castration-resistant prostate cancer (mCRPC) who previously received abiraterone acetate, a novel androgen synthesis inhibitor (ASI). Cancer and Leukemia Group B (CALGB) trial 90401 (Alliance), a phase 3 trial in patients with mCRPC who received docetaxel-based chemotherapy, offered the opportunity to evaluate effect of prior ketoconazole, an earlier generation ASI, on clinical outcomes after docetaxel.MethodsIn CALGB trial 90401, 1050 men with chemotherapy-naive mCRPC were randomized to receive treatment with docetaxel and prednisone that included either bevacizumab or placebo. In total, 1005 men (96%) had data available regarding prior ketoconazole therapy. The observed effects of prior ketoconazole on overall survival (OS), progression-free survival (PFS), prostate-specific antigen (PSA) decline, and the objective response rate (ORR) were assessed using proportional hazards and Poisson regression methods adjusted for validated prognostic factors and treatment arm.ResultsBaseline characteristics between patients who did (N=277) and did not (N=728) receive prior ketoconazole therapy were similar. There were no statistically significant differences between patients who did and those who did not receive prior ketoconazole therapy with respect to OS (median OS, 21.1 months vs 22.3 months, respectively; stratified log-rank P=.635), PFS (median PFS, 8.1 months vs 8.6 months, respectively; stratified log-rank P=.342), the proportion achieving a decline ≥ 50% in PSA (61% vs 66%, respectively; relative risk, 1.09; adjusted P=.129), or ORR (39% vs 43%, respectively; relative risk, 1.11; adjusted P=.366).ConclusionsAs measured by OS, PFS, PSA, and the ORR, there was no evidence that prior treatment with ketoconazole had an impact on the clinical outcomes of patients with mCRPC who received subsequent docetaxel-based therapy. The current results highlight the need for prospective studies to assess for potential cross-resistance with novel ASIs and to define the optimal sequence of therapy in mCRPC.

Published
2013

39. Update on Chemotherapy in the Treatment of Urothelial Carcinoma

Author

Costantini, Carrie and Millard, Frederick

Subjects
Article Subject
Abstract

Urothelial carcinoma is the fifth most common malignancy diagnosed each year in the United States. Neoadjuvant and adjuvant chemotherapy are given to decrease the risk of recurrent or metastatic disease with the more robust clinical data supporting the former. Bladder preservation utilizes a trimodality approach with maximal transurethral resection followed by concurrent chemotherapy and radiation and is appropriate for select patients. Gemcitabine and cisplatin is the current standard of care for first-line treatment in fit patients with metastatic disease. Optimal second-line therapy remains undefined, and targeted agents are under investigation. Clinical trial participation should be encouraged in patients with urothelial carcinoma of the bladder to help improve treatment regimens and outcomes. Synopsis. Chemotherapy is commonly used in the treatment of urothelial carcinoma of the bladder. This paper will review the role of chemotherapy in the neoadjuvant, adjuvant, bladder sparing, and metastatic settings.

Published
2011
Full Text
View/download PDF

40. Abstract A55: Phase 1 results of emibetuzumab (LY2875358), a bivalent MET antibody, in patients with advanced castration-resistant prostate cancer, and MET positive renal cell carcinoma, non-small cell lung cancer, and hepatocellular carcinoma

Author

Banck, Michaela S., primary, Chugh, Rashmi, additional, Natale, Ronald B., additional, Algazi, Alain, additional, Carthon, Bradley C., additional, Rosen, Lee S., additional, Menefee, Michael E., additional, Zhu, Andrew Xiuxuan, additional, Sato, Takami, additional, Moser, Brian, additional, Turner, P. Kellie, additional, Tuttle, Jay, additional, Wang, Xuejing Aimee, additional, Wacheck, Volker, additional, and Millard, Frederick E., additional

Published
2015
Full Text
View/download PDF

41. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma

Author

Milowsky, Matthew I., primary, Dittrich, Christian, additional, Durán, Ignacio, additional, Jagdev, Satinder, additional, Millard, Frederick E., additional, Sweeney, Christopher J., additional, Bajorin, Dean, additional, Cerbone, Linda, additional, Quinn, David I., additional, Stadler, Walter M., additional, Rosenberg, Jonathan E., additional, Lochheed, Melissa, additional, Sen, Paramita, additional, Squires, Matthew, additional, Shi, Michael, additional, and Sternberg, Cora N., additional

Published
2014
Full Text
View/download PDF

43. A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

Author

Small, Eric Jay, primary, Lance, Raymond S., additional, Redfern, Charles H., additional, Millard, Frederick E., additional, Gardner, Thomas A., additional, Karsh, Lawrence Ivan, additional, Dawson, Nancy Ann, additional, McCoy, Candice, additional, Stubbs, Andrew, additional, DeVries, Todd, additional, dela Rosa, Corazon P., additional, Sheikh, Nadeem A., additional, and Shore, Neal D., additional

Published
2013
Full Text
View/download PDF

44. 1832 DOES TIMING OF TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA IMPACT TREATMENT TOXICITY AND SURGICAL COMPLICATIONS? A COMPARATIVE ANALYSIS OF PRIMARY AND ADJUVANT APPROACHES

Author

Patel, Nishant D, primary, Palazzi, Kerrin L, additional, Kopp, Ryan P, additional, Liss, Michael, additional, Mehrazin, Reza, additional, Jabaji, Ramzi, additional, Mirheydar, Hossein, additional, Cohen, Seth, additional, Park, Samuel K, additional, Patterson, Anthony, additional, Kane, Christopher, additional, Millard, Frederick, additional, and Derweesh, Ithaar, additional

Published
2013
Full Text
View/download PDF

45. Reply

Author

Derweesh, Ithaar H., primary, Stroup, Sean P., additional, and Millard, Frederick, additional

Published
2013
Full Text
View/download PDF

46. Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3.

Author

Milowsky, Matthew I., primary, Dittrich, Christian, additional, Duran Martinez, Ignacio, additional, Jagdev, Satinder, additional, Millard, Frederick E., additional, Sweeney, Christopher, additional, Bajorin, Dean F., additional, Cerbone, Linda, additional, Dunn, Robert M., additional, Sen, Paramita, additional, Shi, Michael, additional, Kay, Andrea C. M., additional, Squires, Matthew, additional, and Sternberg, Cora N., additional

Published
2013
Full Text
View/download PDF

47. A QTc study of cabazitaxel in patients with advanced solid tumors.

Author

Wade, James Lloyd, primary, Dakhil, Shaker R., additional, Baron, Ari David, additional, Rottey, Sylvie, additional, Millard, Frederick E., additional, Daugaard, Gedske, additional, Machiels, Jean-Pascal H., additional, Conkright, William A., additional, Sharma, Sunil, additional, Soetekouw, Patricia M.M.B., additional, Yachnin, Jeffrey, additional, Sengeløv, Lisa, additional, van Veldhuizen, Peter, additional, Agarwala, Sanjiv S., additional, Nguyen, TX Quyen, additional, Chadjaa, Mustapha, additional, and Maison-Blanche, Pierre, additional

Published
2012
Full Text
View/download PDF

50. A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871

Author

Lewis, Lionel D., primary, Miller, Antonius A., additional, Rosner, Gary L., additional, Dowell, Jonathan E., additional, Valdivieso, Manuel, additional, Relling, Mary V., additional, Egorin, Merrill J., additional, Bies, Robert R., additional, Hollis, Donna R., additional, Levine, Ellis G., additional, Otterson, Gregory A., additional, Millard, Frederick, additional, and Ratain, Mark J., additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results